Target
NF2
6 abstracts
Abstract
CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers.Org: Cancer Research UK National Biomarker Centre, Royal United Hospitals Bath NHS Foundation Trust, Torbay and South Devon NHS Foundation Trust, Velindre University NHS Trust, Clatterbridge Centre for Oncology NHS Foundation Trust,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.Org: University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Bucksbaum Institute for Clinical Excellence, Section of Hematology/Oncology, The University of Chicago Medicine,
Abstract
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,
Abstract
Hints for reclassification of meningiomas based on the fifth edition of WHO CNS.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd., The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd,
Abstract
Genomic analysis in NF2 meningiomas: Does co-mutation suggest new subgroups?Org: Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China, The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China,